Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com 3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com 3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com 3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com 3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com 3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com 3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com 3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com 3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com 3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com 3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com 3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com 3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com 3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com 3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 3 years ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 3 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 3 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 3 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com 3 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 3 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com 4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com 4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 4 years ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com 4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More